/

Assertio Holdings, Inc.

ASRT US

ASRT USAssertio Holdings, Inc.

United States Composite

0.75

USD

-0.03

(-3.33%)

-2.75EPS Dil.

-0.24P/E

71.29MMarket Cap

Next Earnings

March 6

Held by Insiders

5.60%

Held by Institutions

48.61%

Short % of Float

9.18%

YTD Yield

-63.08%

3Y Yield

15.83%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

- -

LT Borrowings

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

355

306

242

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

138

134

185

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

114

Payables & Accruals

100

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

18.97%

-10.61%

40.54%

Net Income, GAAP

-1,196.49%

-2,347.85%

-11,100.00%

Free Cash Flow

-6.74%

243.83%

1,460.00%

Total Cash Common Dividend

- -

Total Equity

31.88%

31.21%

121.57%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

111

2022

156

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.12

-0.32

0.08

0.10

-0.03

2022

0.20

0.17

0.09

1.83

2.33

2023

-0.07

0.15

-3.42

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Daniel A. Peisert
Full Time Employees: 30
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: 100 South Saunders Road Lake Forest IL United States 60045
CIK: 0001808665
Website: www.assertiotx.com
Business: Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Company Description

CEO: Mr. Daniel A. Peisert
Full Time Employees: 30
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: 100 South Saunders Road Lake Forest IL United States 60045
CIK: 0001808665
Website: www.assertiotx.com
Business: Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.